Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Evaluation of HSPD1 (Heat Shock Protein, 60) as a theranostic target for breast cancer

Award Number: SC1GM136521
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/20/2020
PERIOD OF PERFORMANCE END DATE: 07/31/2025

Group Awards By:

View Award Description

Evaluation of HSPD1 (Heat Shock Protein, 60) as a theranostic target for breast cancer - Our laboratory has used a novel subtractive phage display technique to identify phage ligands that can specifically and selectively bind to epithelial to mesenchymal transitioned (EMT) breast cancer cells. We selected and characterized several phages that had affinity to EMT cells. One of the phages with the foreign peptide sequence CLGLRGSLC bound with greater affinity and specificity to EMT breast cancer and EMT fibroblasts cells. We identified HSPD1 (heat shock protein, 60Kda) as a putative binding partner to CLGLRGSLC phage. Subsequent studies, including bioinformatics dataset analysis, immunoblotting of indolent vs aggressive breast cancer cells, immunohistochemical analysis of primary and metastatic breast cancer tissues showed increased expression of HSPD1 during disease progression and correlates with survival of breast cancer patients. This preliminary engenders the novel hypothesis that HSPD1 might play a role in metastatic progression of breast cancer and the discovery of HSPD1-binding peptide also suggests the use of novel imaging and therapeutic agents based on the selective binding. We hypothesize that HSPD1 is a novel oncogene that can serve as a clinically relevant marker for breast cancer metastasis and an ideal receptor that can be utilized for tumor-targeted drug delivery to metastatic sites. Following specific aims will be pursued: a) to determine if HSPD1 expression correlates with metastatic disease. b) to determine the oncogenic role of HSPD1 in breast cancer development and progression invitro and invivo, c) will aim to develop peptidomimetic targeting system to suppress metastasis based on HSPD1-binding phage peptide fused to proapoptotic moiety D(KLAKLAK)2.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$89,320 )
2026	2023	TUSKEGEE UNIVERSITY	1200 W MONTGOMERY RD	TUSKEGEE INSTITUTE	AL	36088	MACON	USA	Biomedical Research and Research Training	000	4	3/31/2026	NON-COMPETING CONTINUATION	-$89,320
														Subtotal = -$89,320

Issue Date FY: 2023 ( Subtotal = $367,500 )
2023	2023	TUSKEGEE UNIVERSITY	1200 W MONTGOMERY RD	TUSKEGEE INSTITUTE	AL	36088	MACON	USA	Biomedical Research and Research Training	000	4	7/14/2023	NON-COMPETING CONTINUATION	$367,500
														Subtotal = $367,500

Issue Date FY: 2022 ( Subtotal = $367,500 )
2022	2022	TUSKEGEE UNIVERSITY	1200 W MONTGOMERY RD	TUSKEGEE INSTITUTE	AL	36088	MACON	USA	Biomedical Research and Research Training	000	3	6/27/2022	NON-COMPETING CONTINUATION	$367,500
														Subtotal = $367,500

Issue Date FY: 2021 ( Subtotal = $367,500 )
2021	2021	TUSKEGEE UNIVERSITY	1200 W MONTGOMERY RD	TUSKEGEE INSTITUTE	AL	36088	MACON	USA	Biomedical Research and Research Training	000	2	7/29/2021	NON-COMPETING CONTINUATION	$367,500
														Subtotal = $367,500

Issue Date FY: 2020 ( Subtotal = $348,230 )
2020	2020	TUSKEGEE UNIVERSITY	1200 W MONTGOMERY RD	TUSKEGEE INSTITUTE	AL	36088	MACON	USA	Biomedical Research and Research Training	000	1	8/18/2020	NEW	$348,230
														Subtotal = $348,230

Grand Total All Awards = $1,361,410

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Evaluation of HSPD1 (Heat Shock Protein, 60) as a theranostic target for breast cancer

Award Number: SC1GM136521

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/20/2020

PERIOD OF PERFORMANCE END DATE: 07/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer